TechGALA 2025 - Aichi's First International Startup Conference
Join us 4-6 February 2025 to discover Aichi's long history of innovation and manufacturing in Japan.
NAGOYA, JAPAN / ACCESSWIRE / November 11, 2024 / In the startup world there's a lot of talk about ‘disruption,' but Japanese culture doesn't really do disruption. What it does do is have a highly-skilled, self-motivated workforce working unabashedly hard towards clear goals. If you add the ability to innovate to that, then you have a recipe for success.
TechGALA
The place of technology to unlock the future of the Earth
That's the Aichi way of doing things; innovation working within a system, rather than against it. Aichi centers around Nagoya, a manufacturing hub halfway between Tokyo and Osaka, and is long home to many of Japan's major industries. Its biggest claim to fame internationally is being the home of Toyota, but Aichi provides a wealth of components and technologies that you probably used several times already today!
And now, with the launch of TechGALA, Aichi is ready to share its unique take on innovation within a system with the world, in the region's first-ever startup event.
Akihisa Mizuno, Chairman of the Central Japan Economic Federation - one of the organizations responsible for bringing TechGALA to life - said, "our goal is to build an ecosystem where manufacturing and research work together to create internationally competitive startups that leverage deep tech. We hope that TechGALA Japan will serve as a catalyst for startups to flourish."
From the 4th-6th of February 2025 over several venues within Nagoya's vibrant Sakae district, TechGALA will host over 300 guest speakers from both Japan and overseas, a hackathon, a pitch contest, and many other side events.
TechGALA will focus on five core themes: Mobility, exploring borderless future transportation; Sustainable Environment, addressing global efforts to build a resilient Earth; Material, focusing on innovation and evolution in industrial materials; Life Science/Well-Being, highlighting advancements in health and well-being; and Advanced Technology, showcasing cutting-edge tech like AI and robotics to drive societal and industrial transformation.
An impressive lineup of international and local speakers join us to expound on these five key themes. Dr. Adriana Marais, a renowned expert in space exploration, and Marcus Brauchli, Chairman of Blue Ocean and former Executive Editor of The Washington Post, are among the distinguished guests. Other prominent speakers include Professor Seita Emori, a leading climate scientist, Mari Ogiso, Co-CEO of SDG Impact Japan, Rina Sakai, CEO of Fermentation Station, Takaya Matsuda, Co-CEO of HERALBONY, and Christina Yasuda, an expert in digital identity systems at SPRIN-D.
In addition to the main conference, TechGALA will host Aichi's first large-scale pitch contest: The Global Startup Showcase. Designed for both Japanese startups looking to enter overseas markets and global startups aiming to penetrate the Japanese market, startups aligned with TechGALA's core themes are all invited to come and compete. In addition to the winner being awarded a cash prize of one million yen, finalists will be given the opportunity to meet with major Japanese companies, receive support for their expansion into Japan, and participate in side events to discover new partnerships and market development opportunities.
The application window to participate in the Global Startup Showcase is open now until November 15th - time to start preparing your pitch!
Early bird tickets for general admission are also on sale for 30% off until December 4th. Details on how to buy tickets and the full list of speakers and guest judges can be found here: https://techgala.jp/en/
Stay tuned for more info, and we can't wait to see you at TechGALA 2025!
Contact Information
Tech GALA Media
Media Relations
en-contact@techgala.jp
03-6407-9982
Related Images
|
SOURCE: Tech GALA Japan
View the original press release on newswire.com.
TechGALA
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom